SEC Form 4 · accession 0001017491-16-000180
SEELOS THERAPEUTICS, INC. · SEEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Catherine Bovenizer
Officer — VP Finance & CAO
Period of report
May 20, 2016
Accepted (ET)
May 20, 2016 · 6:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001017491
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | May 20, 2016 | A | 50,000 | — | A | 34,594 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Award of 50,000 Restricted Stock Units ("RSUs") under the Issuer's 2012 Stock Long Term Incentive Plan with half of the underlying shares vesting on the Company's receipt of marketing approval of Vitaros in the United States by the Food and Drug Administration on or before December 31, 2018 and the other half of the underlying shares vesting on January 1, 2018, subject to the Reporting Person's continued employment or service to the Issuer through such date.
- F2Not applicable.